Skip to main content

WDR4 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 5 and 94 bp insertion in exon 5.

Be the first to review this product! Submit a review

Images

Western blot - Human WDR4 knockout HeLa cell line (AB265109), expandable thumbnail
  • Sanger Sequencing - Human WDR4 knockout HeLa cell line (AB265109), expandable thumbnail
  • Sanger Sequencing - Human WDR4 knockout HeLa cell line (AB265109), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 5 and 94 bp insertion in exon 5

Alternative names

OTTHUMP00000109401, OTTHUMP00000109402, TRM82, WD repeat protein 4, WD repeat protein domain 4 protein isoform 2, WD repeat-containing protein 4, WDR4_HUMAN, tRNA (guanine-N(7)-)-methyltransferase subunit WDR4

Recommended products

WDR4 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 5 and 94 bp insertion in exon 5.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 5 and 94 bp insertion in exon 5
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
WDR4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The WDR4 protein also known as WD repeat domain 4 functions in the modification of ribonucleic acids. It specifically takes part in the methylation process of N(7)-methylguanine-tRNA (m7G46) where it serves as an important component of the tRNA methyltransferase complex. With an approximate mass of 51 kDa WDR4 shows expression in various tissues throughout the human body contributing to fundamental cellular processes.

Biological function summary

WDR4 plays a role in the maintenance of accurate protein synthesis. It contributes to the stabilization and correct folding of tRNA molecules which are essential for the translation of genetic information from mRNA to proteins. As part of the tRNA methyltransferase complex WDR4 interacts with the METTL1 enzyme highlighting its involvement in precise tRNA modification processes critical for cellular function and proliferation.

Pathways

The function of WDR4 integrates into the broader landscape of the RNA modification pathway. This pathway is tied to the regulation of gene expression and cellular homeostasis. WDR4's activity impacts the efficiency and fidelity of the translation pathway. In this context WDR4 works closely with METTL1 enhancing the stability and functional capacity of tRNA during protein synthesis which is pivotal for the correct transmission of genetic code within cells.

Associated diseases and disorders

WDR4's malfunction or altered expression associates with several conditions including microcephalic primordial dwarfism where its disruption affects brain development and growth. The protein interacts with METTL1 implicated in the same disorder demonstrating the importance of their coordinated function. Additionally alterations in WDR4 expression might link to certain types of cancers where aberrant tRNA methylation affects tumor growth and progression indicating the potential for WDR4 as a therapeutic target.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com